<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Guidance for Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Guidance for Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic; Availability</h1>
    <p class="timestamp">Published: 2012-02-24 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled "Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic." The guidance discusses FDA's intended approach to enforcement of adverse event reporting requirements for drugs, biologics, medical devices, and dietary supplements during an influenza pandemic. The Agency makes recommendations to industry for focusing limited resources on repor...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2012-4288</p>
    <p><strong>Publication Date:</strong> 2012-02-24</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2012/02/24/2012-4288/guidance-for-industry-on-postmarketing-adverse-event-reporting-for-medical-products-and-dietary">https://www.federalregister.gov/documents/2012/02/24/2012-4288/guidance-for-industry-on-postmarketing-adverse-event-reporting-for-medical-products-and-dietary</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2012-4288</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
